Bacterial Vaccines and Therapies - Building a Product Pipeline

Absynth Biologics已经成功地展示了一种开发新的抗菌疫苗和抗体的创新方法。Absynth的技术识别蛋白质，这是利用免疫系统的细菌生存所必需的。到目前为止，该公司已经证明其方法可以预防主要病原体金黄色葡萄球菌(金黄色葡萄球菌)引起的感染，包括耐药品种MRSA(耐甲氧西林金黄色葡萄球菌)。Absynth抗金黄色葡萄球菌疫苗和抗体正处于临床前开发阶段。Absynth技术的一个核心方面是这些蛋白质在细菌王国中的保存程度。因此，在金黄色葡萄球菌中发现的相同靶点也存在于许多其他细菌病原体中。有了这一专有知识，Absynth可以快速启动新的疫苗和抗体计划，以开发产品流水线。该项目的目标是评估更广泛的市场需求，以预防和治疗细菌感染，Absynth的技术可以满足这一需求。Absynth清楚地了解未满足的客户/患者需求、市场规模、驱动因素、动态和竞争，将能够选择这些机会来建立管道。抗生素耐药性以惊人的速度增加，推动了对抗菌疫苗和抗体的需求。到2014年，细菌疫苗市场预计将从39亿美元增长到155亿美元，人们对抗感染抗体产品的兴趣越来越大，只有一种产品Synagis获得许可使用。目前还没有上市的金黄色葡萄球菌疫苗或抗体，销售潜力估计为20亿美元。许多其他细菌感染缺乏疫苗或抗体，包括艰难梭菌引起的医院感染、淋病奈瑟氏菌引起的性传播疾病以及由大肠杆菌引起的社区感染。对于Absynth来说，新的机遇是巨大的。

Absynth Biologics has successfully demonstrated an innovative approach for developing newantibacterial vaccines and antibodies. Absynth’s technology identifies proteins, essential forthe life of bacteria that harness the immune system. To date the Company has shown itsapproach can protect against infections caused by a major pathogen Staphylococcus aureus (S.aureus), including antibiotic resistant variety MRSA (Methicillin Resistant S. aureus). TheAbsynth anti-S.aureus vaccine and antibodies are being advanced in pre-clinical development.A central aspect of the Absynth technology is the degree of conservation of these proteinsacross the bacterial kingdom. Consequently the same targets found in S. aureus also arepresent in many other bacterial pathogens. With this proprietary knowledge Absynth canrapidly initiate new vaccine and antibody programmes to develop a product pipeline.The objective of this project is to assess the broader market needs to prevent and treatbacterial infections, addressable by Absynth’s technology. With a clear understanding ofunmet customer/patient needs, market size, drivers, dynamics and competition, Absynth willbe able to select those opportunities to build a pipeline.Resistance to antibiotics in increasing at an alarming rate, driving the need for antibacterialvaccines and antibodies. The market for bacterial vaccines is expected to grow from $3.9billion to $15.5 billion by 2014 and there is growing interest in anti-infective antibodyproducts with only one, Synagis, licensed for use.There currently are no marketed S. aureus vaccines or antibodies and the sales potential isestimated to be >US $2 billion. Many other bacterial infections lack vaccines or antibodiesincluding hospital infections cause by C. difficile, sexually transmitted diseases caused by N.gonorrhoea and community-based infections caused by E. coli. The new opportunities forAbsynth are significant.